Nicolas Duployez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4275927/publications.pdf

Version: 2024-02-01

91 papers	2,034 citations	218592 26 h-index	276775 41 g-index
91 all docs	91 docs citations	91 times ranked	3077 citing authors

#	Article	IF	Citations
1	Chronic myeloid leukaemia presenting with monocytosis. British Journal of Haematology, 2022, 196, 8-8.	1.2	0
2	Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Advances, 2022, 6, 998-1003.	2.5	88
3	Validation and clinical application of transactivation assays for RUNX1 variant classification. Blood Advances, 2022, , .	2.5	5
4	Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone Marrow Transplantation, 2022, 57, 315-318.	1.3	36
5	Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatology, 2022, 61, 4355-4363.	0.9	14
6	Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group. Leukemia, 2022, 36, 1390-1400.	3.3	2
7	A randomised phase <scp>II</scp> study of azacitidine (<scp>AZA</scp>) alone or with Lenalidomide (<scp>LEN</scp>), Valproic acid (<scp>VPA</scp>) or Idarubicin (<scp>IDA</scp>) in <scp>higherâ€Risk MDS</scp> or low blast <scp>AML</scp>: <scp>GFM</scp>'s â€œpick a winnerâ€•trial, with the impact of somatic mutations. British Journal of Haematology, 2022, 198, 535-544.	1.2	12
8	Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood, 2022, 140, 756-768.	0.6	48
9	Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region. British Journal of Haematology, 2022, 198, 413-413.	1.2	0
10	Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. Blood, 2021, 137, 1424-1428.	0.6	32
11	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	0.6	30
12	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood, 2021, 137, 524-532.	0.6	33
13	The homozygous variant p.Gln1311* in exon 28 of VWF is associated with the development of alloantibodies in 3 unrelated patients with type 3 VWD. Haemophilia, 2021, 27, e491-e494.	1.0	0
14	Germline RUNX1 mutations/deletions and genetic predisposition to hematological malignancies. Hematologie, 2021, 27, 19-31.	0.0	0
15	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study. Blood, 2021, 137, 2827-2837.	0.6	36
16	Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies. Leukemia, 2021, 35, 3304-3308.	3.3	11
17	Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults. HemaSphere, 2021, 5, e552.	1.2	6
18	The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively. Cancers, 2021, 13, 2156.	1.7	4

#	Article	IF	Citations
19	Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications. Expert Opinion on Therapeutic Targets, 2021, 25, 299-309.	1.5	15
20	Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias. Genes Chromosomes and Cancer, 2021, 60, 657-667.	1.5	47
21	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138, 507-519.	0.6	40
22	Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2021, 384, 2163-2165.	13.9	63
23	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	1.7	29
24	Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. Haematologica, 2021, 106, 908-912.	1.7	8
25	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica, 2021, 106, 1767-1769.	1.7	8
26	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Advances, 2021, 5, 5258-5268.	2.5	12
27	Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study. Blood, 2021, 138, 31-31.	0.6	4
28	Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. Blood, 2021, 138, 612-612.	0.6	1
29	Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2928-2928.	0.6	0
30	Controversies about germline RUNX1 missense variants. Leukemia and Lymphoma, 2020, 61, 497-499.	0.6	3
31	Mature neutrophils with Auer rod bundles in CBFB-MYH11-positive acute myeloid leukemia. International Journal of Hematology, 2020, 111, 3-4.	0.7	1
32	Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype. Cancers, 2020, 12, 88.	1.7	4
33	When leukocytes bite off more than they can chew. American Journal of Hematology, 2020, 95, 447-448.	2.0	1
34	Familial myeloid malignancies with germline TET2 mutation. Leukemia, 2020, 34, 1450-1453.	3.3	36
35	Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19. Cancers, 2020, 12, 1992.	1.7	24
36	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. International Journal of Molecular Sciences, 2020, 21, 5626.	1.8	20

#	Article	IF	Citations
37	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Advances, 2020, 4, 1942-1949.	2.5	49
38	13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood, 2020, 136, 946-956.	0.6	41
39	Cytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotype. Leukemia and Lymphoma, 2020, 61, 1772-1774.	0.6	1
40	Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. British Journal of Haematology, 2020, 189, e119-e122.	1.2	9
41	Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia, 2020, 34, 2230-2233.	3.3	1
42	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood, 2020, 135, 542-546.	0.6	62
43	Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively. Blood, 2020, 136, 7-8.	0.6	1
44	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood, 2020, 136, 387-400.	0.6	46
45	Optical Mapping, a Promising Alternative to Gold Standard Cytogenetic Approaches in Acute Lymphoblastic Leukemias: A Blind Comparison on 10 Patients. Blood, 2020, 136, 39-40.	0.6	0
46	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 348-357.	3.3	44
47	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood, 2019, 134, 1351-1355.	0.6	89
48	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. Translational Oncology, 2019, 12, 726-732.	1.7	7
49	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood, 2019, 134, 2414-2416.	0.6	14
50	Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. HemaSphere, 2019, 3, e203.	1.2	13
51	B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. Frontiers in Oncology, 2019, 9, 1374.	1.3	28
52	Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapyâ€refractory Bâ€cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1â€ABL2 Fusion. HemaSphere, 2019, 3, e193.	1.2	4
53	Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature. Leukemia and Lymphoma, 2019, 60, 1827-1830.	0.6	14
54	Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hautsâ€deâ€France AML observatory. American Journal of Hematology, 2019, 94, E24-E27.	2.0	5

#	Article	IF	Citations
55	Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study. Blood, 2019, 134, 1423-1423.	0.6	1
56	Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML. Blood, 2019, 134, 1416-1416.	0.6	5
57	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. HemaSphere, 2018, 2, e31.	1.2	40
58	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. Blood, 2018, 132, 187-196.	0.6	54
59	Detection of a new heterozygous germline <scp>ETV</scp>6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. European Journal of Haematology, 2018, 100, 104-107.	1.1	18
60	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 555-573.	1.8	71
61	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. Leukemia, 2018, 32, 1878-1882.	3.3	8
62	A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. Haematologica, 2018, 103, e575-e577.	1.7	10
63	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. Blood, 2018, 132, 993-993.	0.6	2
64	SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget, 2018, 9, 6478-6489.	0.8	15
65	A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia. Oncotarget, 2018, 9, 33869-33870.	0.8	4
66	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	0.6	0
67	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	5.8	55
68	Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. Annals of Hematology, 2017, 96, 1579-1581.	0.8	30
69	High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones. Leukemia Research, 2017, 53, 1-7.	0.4	18
70	Reactive oxygen species levels control NF-ÎºB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget, 2017, 8, 105510-105524.	0.8	35
71	Multiâ€loci diagnosis of acute lymphoblastic leukaemia with highâ€throughput sequencing and bioinformatics analysis. British Journal of Haematology, 2016, 173, 413-420.	1.2	17
72	Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm withBCR-JAK2fusion transcript. European Journal of Haematology, 2016, 97, 399-402.	1.1	8

#	Article	IF	Citations
73	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood, 2016, 127, 2451-2459.	0.6	198
74	Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Review of Hematology, 2016, 9, 1189-1202.	1.0	19
75	NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. Haematologica, 2016, 101, e133-e134.	1.7	35
76	Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia, 2016, 30, 999-1002.	3.3	86
77	UnlikeASXL1andASXL2mutations,ASXL3mutations are rare events in acute myeloid leukemia with t(8;21). Leukemia and Lymphoma, 2016, 57, 199-200.	0.6	19
78	Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial. Blood, 2016, 128, 1676-1676.	0.6	0
79	Diagnosis of intrachromosomal amplification of chromosome 21 (<scp>iAMP</scp>21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia. Clinical Case Reports (discontinued), 2015, 3, 814-816.	0.2	6
80	Incidence of <scp>ATRX</scp> mutations in myelodysplastic syndromes, the value of microcytosis. American Journal of Hematology, 2015, 90, 737-738.	2.0	15
81	Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Review of Hematology, 2015, 8, 43-56.	1.0	28
82	Place de la biologie molÃ©culaire pour le diagnostic et le suivi des leucÃ©mies aiguÃ«s. Revue Francophone Des Laboratoires, 2015, 2015, 51-64.	0.0	1
83	ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis. Blood, 2015, 126, 302-302.	0.6	2
84	Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1â€RUNX1T1 fusion quantification on genomic DNA. American Journal of Hematology, 2014, 89, 610-615.	2.0	21
85	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124, 1445-1449.	0.6	105
86	Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4629-4629.	0.6	0
87	Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia. Blood, 2014, 124, 2360-2360.	0.6	0
88	Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis. Blood, 2014, 124, 1007-1007.	0.6	0
89	Mixed phenotype acute leukaemia with <scp>B</scp>urkittâ€like cells and positive peroxidase cytochemistry. British Journal of Haematology, 2013, 163, 148-148.	1.2	5
90	New-generation sequencing (NGS) in hematologic oncology laboratories. Hematologie, 2013, 19, 112-122.	0.0	2

#	Article	IF	Citations
91	Minimal Residual Disease Monitoring In t(8;21) Acute Myeloid Leukemia Based On RUNX1-RUNX1T1 Fusion Quantification On Genomic DNA. Blood, 2013, 122, 1353-1353.	0.6	0